Enclomiphene Citrate vs AndroGel: Cost and Access Head-to-Head

How Each Drug Works and Why It Matters for Cost

Enclomiphene citrate is a selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the hypothalamus and pituitary, prompting the body to increase its own luteinizing hormone (LH) and follicle-stimulating hormone (FSH) output. The result is higher endogenous testosterone production without shutting down the hypothalamic-pituitary-gonadal (HPG) axis. In the Kim et al. trial (BJU International, 2016), enclomiphene restored serum testosterone to the eugonadal range in men with secondary hypogonadism while preserving spermatogenesis [1].

AndroGel delivers exogenous testosterone transdermally. The Testosterone Trials (TTrials) confirmed that daily application of topical testosterone raised serum T concentrations into the normal range across multiple functional domains in men 65 and older with low testosterone [2]. Because it supplies testosterone directly, exogenous gel therapy suppresses LH and FSH through negative feedback, which reduces or halts sperm production in most men within 3-6 months of continuous use [3].

This mechanistic split drives much of the cost and access divergence between the two options. The drug that preserves fertility (enclomiphene) sits outside the FDA-approved formulary system. The drug that suppresses fertility (AndroGel and its generics) sits squarely inside it.

Direct Cost Comparison: Brand, Generic, and Compounded Pricing

Brand-name AndroGel 1% (1.62%) carries a wholesale acquisition cost that translates to roughly $500-700/month at retail without insurance, depending on the pharmacy and packet size. Generic testosterone gel formulations from manufacturers like Perrigo and Teva reduced this figure substantially after patent expiry, with GoodRx cash prices ranging from $30-120/month for a 30-day supply of testosterone gel 1% [4]. Men with commercial insurance or Medicare Part D typically pay a copay between $10 and $50 for generic testosterone gel, since the Endocrine Society's 2018 Clinical Practice Guideline endorses testosterone therapy for confirmed hypogonadism with two morning serum T levels below 300 ng/dL, giving payers clinical justification for coverage [5].

Enclomiphene citrate occupies a different pricing tier. It is not commercially manufactured by a large pharmaceutical company for the U.S. market. Men access it primarily through compounding pharmacies or telehealth platforms that partner with 503B outsourcing facilities. Monthly costs typically range from $60-150 depending on dose (12.5-25 mg daily), pharmacy, and whether the prescription comes through a telehealth membership that bundles lab monitoring [6].

The pricing gap narrows or even reverses when you compare compounded enclomiphene against brand AndroGel. But the clinically relevant comparison is compounded enclomiphene ($60-150/month, usually cash-pay) versus generic testosterone gel ($30-80/month with insurance). For men with functional insurance coverage, generic testosterone gel is often the cheaper option at the pharmacy counter.

Insurance Coverage and Formulary Access

The formulary divide between these two drugs is stark. Testosterone gel has been FDA-approved since 2000 and appears on virtually every major commercial and Medicare Part D formulary in the United States. Prior authorization requirements exist but are well-established: most payers require two morning serum total testosterone levels below 264-300 ng/dL (threshold varies by plan), documented symptoms, and sometimes a trial of lifestyle modification [5].

Enclomiphene citrate has no FDA approval for male hypogonadism. The compound was studied under the brand name Androxal by Repros Therapeutics, which received a Complete Response Letter from the FDA in 2015 citing concerns about the assay used to measure testosterone and requesting an additional clinical trial. The program was subsequently abandoned. Without an approved New Drug Application (NDA), enclomiphene does not appear on standard formularies. Commercial insurance plans and Medicare Part D almost never cover compounded enclomiphene prescriptions, placing the full cost burden on the patient [6].

Some health savings account (HSA) and flexible spending account (FSA) arrangements allow reimbursement for compounded prescriptions when accompanied by a valid prescription, but this varies by plan administrator. Men choosing enclomiphene should confirm HSA/FSA eligibility with their specific plan before committing.

Fertility Preservation: The Deciding Clinical Variable

For men who want to maintain or restore fertility, cost becomes secondary to a binary clinical question: does the therapy preserve sperm production? Exogenous testosterone, including AndroGel, suppresses intratesticular testosterone concentrations by 95% or more through HPG axis suppression, reducing sperm counts to oligospermic or azoospermic levels in the majority of men within weeks to months. A 2019 meta-analysis published in Fertility and Sterility reported that recovery of spermatogenesis after testosterone discontinuation took a median of 6 months but could extend beyond 12 months, and a small percentage of men may not fully recover [7].

Enclomiphene, by contrast, stimulates endogenous gonadotropin production. The Kim et al. data showed that men on enclomiphene maintained sperm concentrations comparable to baseline, while men on topical testosterone experienced significant declines [1]. Dr. Ronald Swerdloff, a researcher in male reproductive endocrinology at UCLA, has noted: "For hypogonadal men who wish to preserve fertility, SERMs like clomiphene represent a reasonable alternative to exogenous testosterone, provided the clinician monitors both hormone levels and symptom response."

This makes the cost question more nuanced than a simple price-per-month comparison. A man in his early 30s with secondary hypogonadism who plans to conceive within the next 2-5 years might save money on generic testosterone gel now but face $10,000-20 to 000 in fertility treatment costs later if spermatogenesis does not fully recover. Enclomiphene's higher out-of-pocket monthly cost may represent a net savings over a 5-year reproductive planning horizon.

Efficacy: Testosterone Normalization Rates

Both drugs accomplish the primary pharmacologic goal of raising serum total testosterone into the reference range (300-1 to 000 ng/dL), but they do so through different physiologic pathways with different response profiles.

In the TTrials, men using testosterone gel 1% achieved a mean serum T of approximately 500 ng/dL at 12 months, with over 75% of participants reaching the target range [2]. Response was dose-dependent and could be titrated by adjusting the amount of gel applied daily (typically 5-10 g).

Enclomiphene 25 mg daily in the Kim et al. trial raised mean serum testosterone from approximately 228 ng/dL at baseline to 446 ng/dL at 12 weeks, with 86.7% of subjects reaching the eugonadal range [1]. The Endocrine Society guideline does not endorse SERMs as first-line TRT but acknowledges their off-label use, particularly when fertility is a concern [5].

A key difference: testosterone gel delivers a steady exogenous supply with predictable pharmacokinetics. Enclomiphene depends on intact Leydig cell function, meaning men with primary hypogonadism (testicular failure) will not respond adequately. The 2018 Endocrine Society guideline specifically recommends against SERM use in men with primary hypogonadism, defined by elevated LH levels above 9.4 IU/L combined with low testosterone [5].

Side-Effect Profiles and Monitoring Costs

Monitoring requirements differ between the two therapies, and those differences carry cost implications.

Testosterone gel requires periodic monitoring of serum total testosterone (trough level, drawn 2-4 hours after application), hematocrit, PSA, and lipid panel. The FDA's boxed warning for testosterone products highlights cardiovascular risk and polycythemia (hematocrit >54%), which may necessitate dose reduction, therapeutic phlebotomy, or therapy discontinuation [8]. Skin transfer to female partners or children is another safety consideration requiring education and adherence to application-site hygiene protocols.

Enclomiphene monitoring includes serum testosterone, LH, FSH, estradiol, and hematocrit, with the addition of estradiol being important because SERM therapy can increase circulating estrogen levels. Visual disturbances, though rare with enclomiphene (more commonly associated with the zuclomiphene isomer in racemic clomiphene), require clinical vigilance. Hot flashes occur in roughly 5-10% of men using SERMs for testosterone optimization [1].

The lab panels are comparable in cost ($50-150 per draw at commercial lab pricing without insurance), and both therapies typically require labs at baseline, 6-8 weeks, and then every 6-12 months once stable. Testosterone gel's Schedule III status means the prescription itself carries DEA oversight and cannot be called in to pharmacies in some states without an original written prescription or e-prescribing through an approved system. Enclomiphene, as a non-controlled substance, faces no such dispensing restrictions.

Prescribing and Access Logistics

Getting a testosterone gel prescription filled is straightforward. It is stocked at every major retail pharmacy chain (CVS, Walgreens, Walmart, Rite Aid) and available through mail-order pharmacy benefit managers. Refills require a valid prescription from a licensed provider but face no supply-chain bottlenecks.

Enclomiphene access involves more steps. Because the drug is compounded, it must be sourced from a compounding pharmacy (503A) or outsourcing facility (503B). Not all compounding pharmacies carry enclomiphene citrate powder, and quality can vary between facilities. The FDA's guidance on compounded drugs requires that compounded products be prescribed for an individual patient by a licensed prescriber and prepared by a licensed pharmacy [9]. Men using telehealth platforms for enclomiphene typically receive their medication by mail from a partnered 503B facility, which simplifies logistics but limits pharmacy choice.

State-level prescribing regulations also affect access. Some states restrict the prescribing of compounded hormonal agents through telehealth without an initial in-person visit. Others have placed enclomiphene on watch lists due to its unapproved status for this indication. Clinicians should verify their state pharmacy board's current position before prescribing.

Who Should Choose Which Drug

The decision between enclomiphene and testosterone gel is not purely financial. It maps to a clinical decision tree that weighs four variables: fertility goals, hypogonadism etiology, insurance coverage, and convenience preference.

Testosterone gel is typically the better fit for men with confirmed hypogonadism who have completed family building, have insurance that covers generic testosterone gel, prefer the simplicity of a retail pharmacy pickup, or have primary hypogonadism where SERMs will not work. The cost advantage of $10-50/month with insurance is meaningful for men on a fixed budget.

Enclomiphene is typically the better fit for younger men with secondary hypogonadism who want to preserve or restore fertility, men who wish to avoid exogenous testosterone's regulatory classification as a Schedule III substance, or men who are willing to pay $60-150/month out of pocket in exchange for maintaining their HPG axis function. The American Urological Association's 2018 guideline on testosterone deficiency recommends SERMs as an alternative to testosterone for men desiring fertility, though it notes the evidence base is smaller than for exogenous testosterone [10].

Dr. Mohit Khera, a professor of urology at Baylor College of Medicine, has stated: "We routinely use clomiphene or enclomiphene in younger hypogonadal men who want to preserve their fertility options. The evidence supports that these agents normalize testosterone while maintaining spermatogenesis, which exogenous testosterone simply cannot do."

Switching Between Therapies

Men who start on one therapy and need to switch face different timelines depending on the direction of the transition. Switching from enclomiphene to testosterone gel is straightforward: discontinue the SERM, allow a 5-7 day washout, and initiate testosterone gel at the standard starting dose. Lab confirmation of testosterone levels should occur 4-6 weeks after the switch.

Switching from testosterone gel to enclomiphene requires patience. The HPG axis needs time to recover from suppression. LH and FSH levels may take 4-12 weeks to normalize after discontinuing exogenous testosterone, depending on duration of prior therapy. During this recovery window, men often experience a symptomatic trough with fatigue, low libido, and mood changes. Some clinicians bridge this gap with a short course of human chorionic gonadotropin (hCG) to stimulate testicular function while the pituitary recovers, though hCG availability has been constrained since the FDA's 2020 action reclassifying it as a biologic under the BPCIA [11].

The Bottom Line on Total Cost of Therapy

A 12-month cost projection clarifies the financial picture. For a man with commercial insurance covering generic testosterone gel: approximately $360-600/year in copays, plus $200-400 in labs (2-3 draws), totaling roughly $560-1,000/year. For a man paying cash for compounded enclomiphene: approximately $720-1,800/year in medication, plus $200-400 in labs, totaling roughly $920-2,200/year. These projections exclude the cost of the initial consultation, which ranges from $0 (covered by insurance for testosterone gel) to $50-200 (typical telehealth platform fee for enclomiphene).

The fertility variable can invert this calculation entirely. A single cycle of intracytoplasmic sperm injection (ICSI) costs $15,000-25,000 on average in the United States. If exogenous testosterone causes prolonged azoospermia requiring assisted reproduction, the cumulative cost of "cheaper" testosterone gel dwarfs years of enclomiphene therapy.

Men starting TRT should discuss fertility planning with their prescribing clinician before their first dose, not after suppression has already occurred.